Member Info for Ralphiebabe

Noticed presentation time is 14:00, maybe news of TRHC deal?

Final results due by end of month or beginning of October, if not given before, expect news on deal then.

Few tweets this morning.

https://twitter.com/physiomics/status/1404740229991391236?s=21

https://twitter.com/physiomics/status/1404740233615323137?s=21

https://twitter.com/physiomics/status/1404739052553768962?s=21

This abstract specifies the dosing application is for the use with patients with Prostate Cancer.

Thanks for all your research.

Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes

Don’t forget Arjuna Theraputics there with AG5 abstract.
https://www.abstractsonline.com/pp8/#!/9325/presentation/3548

Was posted yesterday, delayed showing by lose.
Maybe this afternoon???

Expect RNS tomorrow mentioning the 2 abstracts they’ve developed.

The way it’s going, 29 means take sp down a notch.

What’s with 29 buys, had one today, yesterday and Monday. For a few weeks have had different values in the 20’s, am I just being neurotic that there’s some meaning to this. LOL.

https://twitter.com/Borg74/status/1369976651333918720?s=20

In limbo at moment. Presentation 11:00am tomorrow, depends if anything new is revealed, if so should have more momentum.

Not sure air it was a one off fee or Pyc will get revenue, ( at moment unable to find runs of contract). Following is case study of CP-506 from May 2019.

https://www.physiomics.co.uk/wp-content/uploads/2019/05/Convert-case-study-vfinal.pdf

On the ball this morning, 3 different article tweets in last hour.

Physiomics tweet about CP-506, which they carried out for convert pharma.
Following from convert site.
12 Feb TUMAGNOSTIC – Phase 1 clinical trial
Posted at 09:59h in News by Convert Editor
Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, has obtained very promising pre-clinical results with CP-506 drug, a new and improved Hypoxia Activated Prodrug. The company is finalising its Clinical Trial Application to obtain regulatory approval for the launch of its tumor agnostic Phase I Clinical Trial in 2021. This will be a first in human dose escalation study to determine the safety, pharmacokinetics, pharmacodynamics and phase 2 recommended dose. At the same time, we will check for the first indication of antitumor effect in humans.
CP-506 will be tested in both monotherapy, with patient selection based on validated biomarkers, as well as in combination with standard treatments such as immune checkpoint inhibitors

Quote from Physiomics.
Specialties
Oncology, Biotechnology, Drug discovery and development, Predictive modelling, Quantitative systems pharmacology, AI, Machine Learning, and PK/PD
https://www.linkedin.com/company/physiomics-plc

550,000 bought in different quantities between 18:25 - 18:55, showing rise 47% ???

When bid gets to 8.1 -8.2 will see more sells going through.

Ask price showing 8.3, I think the trades at 7.95 to 8 are buys as sp would have dropped by now if they were all sells.